Graphical compilation of AEs over time with continuous BTK and fixed-duration BCL2 inhibitor–based therapy from phase 3 frontline CLL trials in older/unfit patients with mature follow-up. The most frequent AEs of any grade occurring on an annual basis for acalabrutinib and of clinical interest for ibrutinib are shown. For obinutuzumab plus venetoclax, the most frequent AEs grade 3 and higher are shown during or after therapy. URTI, upper respiratory tract infection. Data modified with permission from Sharman et al,⁵ Barr et al,⁹ and Al-Sawaf et al.²³